However, although the determination of ROS1 is mandatory according to guidelines, real-world evidence obtained from Lung Cancer Biomarker Testing Registry (LungPath) show that ROS1 fusions were not determined in almost half of the samples of patients with NSCLC (testing rate: 58.1%) [15]. Here, ROS1 is linked to non-small cell lung carcinoma.